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The Papanicolaou Society of Cytopathology has developed a set of guidelines for 
pulmonary cytology including indications for bronchial brushings, washings and endobronchial 
ultrasound guided transbronchial fine needle aspiration (EBUS-TBNA), technical 
recommendations for cytological sampling, recommended terminology and classification 
schemes, recommendations for ancillary testing and recommendations for post-cytological 
management and follow-up.  All recommendations are based on the expertise of the authors, an 
extensive literature review and feedback from presentations at national and international 
conferences.  This document selectively presents the results of these discussions. 
The present document summarizes recommendations regarding techniques used to obtain 
cytological and small histologic specimens from the lung and mediastinal lymph nodes including 
rapid on site evaluation (ROSE), and the triage of specimens for immunocytochemical and 
molecular studies. 
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In an effort to standardize respiratory cytology practice, the Papanicolaou 
Society of Cytopathology (PSC) developed a set of guidelines.  The standardized 
terminology and nomenclature for respiratory cytology have recently been 
published,
1
along with the consensus recommendations for the utilization of 
ancillary studies for diagnosis.
2
  The following is Committee II report on 
guidelines for techniques utilized for respiratory sampling that complements the 




Exfoliative Cytology Sampling Techniques 
A. Sputum 
i. Spontaneous Sputum 
Spontaneous sputum is the simplest method of collecting a respiratory specimen for 
cytological examination. Its reported sensitivity in the literature ranges from 42% to 97% and 
specificity ranges from 68% to 100%, primarily as a result of lack of standardized programs for 
its collection and processing among laboratories, with a pooled sensitivity of 66% and specificity 
of 99%. Spontaneous sputum samples have a sensitivity of 71% for central tumors versus 49% 
for peripheral tumors.
4
 Although it has a lower sensitivity relative to other methods, it still has a 
role in the diagnosis of patients with suspected lung masses and is recommended as the initial 
test in patients who present with central lesions with or without metastasis and those who are at 
high risk for semi-invasive procedures.
4
 Despite its lower sensitivity, sputum is a noninvasive, 
simple and cost effective method that is consequently used particularly in countries with limited 
resources.  
The patient is instructed to cough deeply and to expel the contents into a sterile container.  
A morning pooled sample is ideal when looking for cancer,
5
 and the diagnostic rate is 
proportional to the number of samples examined.  The optimal number is three samples for the 
diagnosis of cancer and five samples to exclude cancer.
6
 While diagnostic accuracy approaches 
95% when five sequential samples are submitted,
7
 additional samples are not contributory.
8
 In 
cases of tuberculosis, examination of three early morning sputum samples on consecutive days 
approaches the sensitivity of a single sputum specimen submitted for culture.
9
  The specimen 
should be stored at 4°C and transferred to the lab immediately for processing.  However, in cases 
of bacterial culture, results were unaffected by storage at room temperature for up to 6 hours, and 
could be stored up to 48 hours at 4°C.
10
  Prolonged exposure to ambient temperature does not 
adversely affect the yield of samples for acid-fast bacilli. Unfortunately, a review of studies 
assessing macroscopic and/or microscopic sputum quality and the impact of pre-sputum 
collection interventions did not result in definitive conclusions due to the paucity and 
heterogeneity of available data.
11
 
Several studies have shown that collecting sputum in liquid based cytology (LBC) collecting 
media such as CytoLyte® or CytoRich red® and subjecting the sputum to homogenization 
during the liquid based preparation resulted in more cellular samples, better quality and higher 
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sensitivity with less unsatisfactory and atypical diagnosis when compared to the traditional pick 
and smear method of preparation.  This processing techniques is particularly useful in evaluating 
sputums collected from patients with suspected lung cancer.  A complementary cell block 
improved the sensitivity and allowed the performance of immunohistochemistry and acceptable 
DNA extraction for molecular testing.
12-14
 
ii. Induced Sputum Collection 
Induced sputum provides better quality specimens and better diagnostic yield in small 
lesions than spontaneous sputum.
15
 In the setting of possible infection, attempting induction 
early, before starting antibiotics, may increase diagnostic yield.
16
 While some authors have 
recommended mouth rinsing, spitting out saliva, using nose clips, and/or brushing teeth prior to 
sputum collection, the value of these procedures is unclear and may add unnecessary complexity 
to the protocol.
17
 The technical aspects are as follows: bronchodilator (200 µg inhaled 
salbutamol) is administered to prevent bronchospasm; patient breathes saline (0.9 to 6%) through 
nebulizer for 15-30 minutes, patient is asked to cough or spit every five minutes or whenever 




 In cases submitted to microbiology, no statistically significant differences were found 
between the yield of induced and spontaneous sputum samples.
18
 Although sputum induction 
may provide an adequate sample more frequently than spontaneous sputum, it is more costly and 
may not result in more patients starting treatment for mycobacterial infection.
19
 Yield for acid-
fast bacilli smears and culture increases with repeated sputum induction.
20
 However, a mix of 
unsupervised, supervised, and induced sputum may be more practical than three induced sputum 
specimens.
21
 In a subset of patients, chest physiotherapy for bronchial clearance may be helpful 
as an alternative method for obtaining sputum.
22
 
 While induced sputum should be processed within two hours, examination of cell counts 
can be delayed for up to nine hours with refrigeration at 4°C.
23
 Induced sputum samples 
collected from patients with suspected cancer can be processed by liquid based preparations as 
described above. 
iii. Post-Bronchoscope Sputum (PBS) 
A post-bronchoscopy sputum smear may be helpful in combination with bronchoalveolar 
lavage particularly for the detection of pulmonary tuberculosis (TB) in patients with suspected 
pulmonary TB who had either three negative sputum smears or could not expectorate.
24
 Post-
bronchoscopy sputum analysis can increase diagnostic yield in patients who are smear negative 
or non-productive of sputum.
25,26
 
 Once transbronchial exfoliative samples are retrieved, the patient is placed in the supine 
position while the selector catheter is in position and 10 mL of sterile saline are rapidly injected.  
The catheter is then withdrawn and the patient turned on his side with the affected lung being 
uppermost.  The patient is then instructed to cough into a container.
27
 alternatively patients could 
be asked to provide a sputum sample if they become productive in the hours following the 
bronchoscopy procedure. 
25
 If the specimen is collected for microbiological testing, the specimen 
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needs to be fresh for special stains and cultures.  Sputum specimens sent to the cytology 
laboratory should be handled similarly to the other sputum samples as described above. 
B. Specimens Collected During Bronchoscopy 
i. Bronchial Brush 
 If a brush is indicated, a Teflon tube is inserted with a nylon brush mounted within the 
end of the tube. The brush is then advanced beyond the tube over the suspected area and moved 
back and forth vigorously.  The goal is to brush the lesion directly and entrap bits of the lesion on 
the bristles.
28
 The brush is then partially pulled back into the Teflon tube and both are 
withdrawn. The sample is consequently submitted according to the laboratory policies, which 
may include immediate smear preparation and alcohol fixation and/or rinsing in saline or other 
preservatives.  This technique demonstrates better yield when a central visible lesion is targeted, 
as opposed to submucosal or peripheral lesions.  If multiple areas are to be sampled and a tumor 
is recognized, it should be brushed last to prevent cross-contamination by cancer cells.
29
 
ii. Bronchial Wash and Bronchoalveolar Lavage (BAL) 
Once the tracheobronchial tree is inspected, the bronchoscope is wedged into the selected 
bronchus. Normal saline at room temperature with total volume of 100-300 mL is instilled 
through the bronchoscope, divided into three to five aliquots. Suction pressure less than 100 mm 
Hg or low enough to prevent visible airway collapse is applied. Optimal sampling should retrieve 
≥30% of the instilled volume. The procedure should be stopped if less than 5 % of the instilled 
aliquot is recovered.
30,31
 Alternatively, a bronchial wash may be used to sample the airway 
surface if a lesion is identified.  Smaller volumes of room temperature normal saline are instilled 
(5-50 mL). The smaller volumes may be beneficial when performing this diagnostic procedure 
on a marginally stable patient.   
For both bronchial wash and bronchoalveolar lavage, 5-15 mL of fluid are required for 
basic microbiologic analysis and 10-20 ml are needed for cellular analysis such as cell counts 
and/or biomarkers for interstitial lung disease. The collected specimens should be kept at room 
temperature if immediate transportation and processing are expected. If a delay of 30-60 min is 
anticipated, the specimens should be transported on ice (4°C). If a delay more than 60 min is 
expected, the specimen should be centrifuged and resuspended in nutrient-supplemented medium 
(MEM or RPMI). The resuspended specimen can be stored at (4°C) for 24 hours. If 
centrifugation is not available, MEM or RPMI could be added to the pooled lavage and the 
specimen can be stored at (4°C) for up to 12 hours.
30
  Again, for cytological evaluation, the 
sample can be collected directly into one of the LBC collecting media. 
 Warming the 0.9% sterile saline to 37°C may reduce cough and bronchospasm, but most 
use saline at room temperature.
32
 Suctioning under low pressure (25-100mmHg) avoids collapse 
of distal airways and trauma to the mucosal surface.
32
 There is variation in the volume of fluid 
used for bronchoalveolar lavage, ranging from 100-300 mL in each lung segment or subsegment 
sampled; smaller volumes are more likely dominated by a “bronchial” washing component.
32
 
There is also variation in the number of aliquots/doses over which the saline is infused. The 
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bronchoscope should be maintained in the wedged position throughout the procedure to avoid 
contamination from the large airways.  Dwell time should be minimized. 
  The right middle lobe (RML) or lingula are standard sites for BAL sampling, unless 
there are localized findings on imaging.
32
 The RML is associated with highest volume of return 
for nontargeted BAL.
33
 Yield is generally better for central rather than peripheral lesions.  
Additional material can be captured from a guide sheath flush, which may have a higher 
diagnostic yield than bronchoalveolar lavage.
34
 
 There is no data to support sending the first aliquot for microbiology and the subsequent 
aliquots for cellular analysis versus pooling all the aliquots.
35
 The volume of fluid recovered as 
well as the percent of fluid returned should be reported for the pooled specimen to ensure 
adequate recovery.
36





Transbronchial Sampling Techniques 
A. Endobronchial Ultrasound Guided Sampling 
i.  Background 
Endobronchial ultrasound (EBUS) is a bronchoscopic technique, first described in 2006, 
that uses ultrasound technology to visualize structures within the airway wall, lung, 
mediastinum, and hila.
37-39
 Two types of EBUS exist: radial probe EBUS (RP-EBUS / equipped 
with a 20-30MHz probe) and convex probe EBUS (CP-EBUS / equipped with a 7.5MHz probe).  
For the purposes of this guideline, “EBUS” refers to the CP-EBUS type which is the one relevant 
for mediastinal/hilar nodal biopsy. There are multiple published reviews incorporating a 
comprehensive discussion of indications, contraindications, and potential complications of 
EBUS bronchoscopy.  This section will focus for the approach of EBUS sampling of hilar and 
mediastinal lymph nodes for staging of lung cancer.  
EBUS has an established role in the diagnosis and staging of patients with lung cancer 
and is able to access more nodal stations than the traditional approach of cervical 
mediastinoscopy.
40
 Lymph node analysis is a critical piece of the tumor-node-metastasis (TNM) 
staging system that is standard for the work-up of patients with non-small cell lung cancer 
(NSCLC).  EBUS should be the initial procedure for sampling mediastinal and hilar lymph nodes 
that are suspected to harbor loco-regional metastatic disease.  
ii. General Approach 
Patients who already have a diagnosis of lung cancer from tissue sampling of their primary lung 
lesion, but lack staging information, will often proceed to EBUS lymph node staging when 
multidisciplinary oncologic planning deems it appropriate.  If there is a clinical suspicion of lung 
cancer, but no diagnostic tissue confirmation, attempts should be made to both diagnose and 
stage during the same bronchoscopic procedure.  Multiple modalities, including transbronchial 
biopsies, brushings, and lavage, with advanced guidance strategies, like software navigation,
41
 





 and peripheral radial ultrasound,
43
 can be used to confirm the lung 
cancer diagnosis during the same EBUS staging procedure.  
In general, the mediastinal and hilar lymph nodes accessible by EBUS include 2R, 2L, 
3p, 4R, 4L, 7, 10R, 10L, 11R, and 11L (Fig. 1). EBUS cannot access paraesophageal lymph 
nodes, and while EBUS can access subaortic level 5-6, it tends to be less accurate and associated 
with more risks.
44
  To access those lymph nodes, EBUS can be done in conjunction with 
transesophageal endoscopy (EUS).
45
 Though there is data to support the use of ultrasound echo-
texture characteristics to differentiate between malignant and benign lymph nodes, 
46,47
 lymph 
nodes that are 0.5cm or greater in short-axis diameter on EBUS analysis should be considered for 
transbronchial needle aspiration (TBNA).  Thorough evaluation of bilateral hila and mediastinum 
should be performed during the EBUS evaluation in light of the false-negative rate of nuclear 
and radiologic staging.
48,49
 EBUS-BNA of enlarged mediastinal/hilar lymph nodes should be 
performed in a systematic fashion, bearing in mind the laterality of the suspected primary lung 
lesion.  For instance, if a patient presents with a spiculated right upper lobe pulmonary nodule 
and an enlarged subcarinal lymph node on CT evaluation, but does not yet have a confirmed 
diagnosis, the recommended approach is EBUS bronchoscopy with systematic scanning and 
TBNA of enlarged lymph nodes from the furthest contralateral lymph node space (“highest 
stage”) to the closest ipsilateral lymph node space (“lowest stage”).  This allows for use of a 
single EBUS needle for the whole procedure while minimizing the risk for contamination and 
false “up-staging” of the patient. Rapid on-site evaluation (ROSE) of aspirated material from the 
subcarinal lymph node (Fig. 2) should be performed as confirmation of diagnostic material 
which would obviate the need for biopsy attempts of the primary lesion, which carries a higher 
peri-procedural risk than EBUS-TBNA.  If ROSE does not confirm diagnostic material, the 
bronchoscopist should consider transitioning to brushings, biopsies, and lavage of the lung 
nodule.  
iii. Technical Approach 
The bronchoscopist should remember the specifics of the airway view offered by the 
EBUS bronchoscope when intubating the patient and navigating the airways.  The EBUS 
bronchoscope offers an 80
o
 visual field of view at a visual angle of 35
o
 forward oblique. The 
ultrasound view is parallel to the shaft of the bronchoscope, with an angle of 90
o
 (Fig. 3).  The 
balloon attached to the probe can be gently inflated with saline to allow optimal apposition with 
the airway wall for best ultrasound viewing.  Color flow and Doppler measurements can be 
performed to identify vascular and cystic structures.  Caliper measurements can be performed on 
the ultrasound image to assess lymph node size.  
In real-time with ultrasound viewing of an enlarged lymph node, a transbronchial needle 
(21 or 22 G retractable sharp beveled needle with a stylet contained within a flexible catheter) 
can be inserted through the working channel of the bronchoscope.  Once the catheter emerges 
from the bronchoscope, the needle is pushed through the airway wall and into the target lymph 
node under ultrasound visualization.  Suction can be applied and the catheter is agitated 20-30 
times per pass.  Once sampling is complete, suction is released and the needle is pulled into the 
catheter and the whole system is removed from the bronchoscope.  If the sample is being sent for 
cytological analysis without ROSE, the aspirated material should be expelled into a sterile 
sample cup containing a few milliliters of saline using a combination of saline/air flushes and 
stylet insertions through the needle or rinsed in LBC collecting media.  If the sample is being 
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evaluated by ROSE, the needle should be extended onto a slide and the stylet inserted gently 
through the needle until sufficient material has been expelled onto the slide.  The remaining 
sample within the needle can be expelled into a sterile sample cup as above. An average of three 
passes per lymph node should be performed.
50,51
 There is data to support the utility of additional 
passes to obtain sufficient material for molecular analysis.
52
 
Traditionally the 22 G needle is chosen during EBUS bronchoscopy because the degree 
to which it stiffens the tip of the EBUS bronchoscope is less than that of the 21 G needle.  This is 
an important issue in lymph node stations where appropriate apposition may be suboptimal and 
the insertion of the larger 21 G needle makes it even more difficult (e.g. the paratracheal spaces.) 
Some experts believe the 21 G needle can produce “core-biopsy-like” material to work-up 
suspected lymphoma diagnoses or is able to acquire more tissue for molecular profiling of lung 
cancer cells.  However, studies have produced conflicting results regarding specimen adequacy 
and diagnostic yield between the two needle sizes.
53-55
 There have been efforts to develop larger 
gauge needles and miniature forceps (to obtain transbronchial lymph node biopsies with 
preserved nodal architecture) appropriate for the EBUS bronchoscope, but further studies will 
need to be done to confirm their utility. A recent pilot study evaluating the Echo Tip ProCore 
needle
® 




Recently, new 19 G EBUS needle became available. Tyan et al. reported their experience 
with the new needle on 47 patients with hilar and mediastinal lymphadenopathy in three centers. 
The diagnostic yield for malignancy, sarcoidosis and reactive lymph node hyperplasia was 89%, 
93% and 83%. All 13 patients diagnosed with adenocarcinoma by the 19 G needle had sufficient 
tissue for genetic studies. Further studies and direct comparison with the 22 G and 21G are 




B. Endobronchial Sampling Techniques of Pulmonary Parenchymal Lesions  
Sampling techniques for pulmonary parenchymal lesions (PPLs) by endoscopic means may 
be performed via brushing, needle aspiration, forceps biopsies or any combination of the 
aforementioned techniques.  Relatively newer techniques such as radial endobronchial 
ultrasound and navigational bronchoscopy or a combination of both procedures may add some 
diagnostic accuracy to the procedure.  Overall diagnostic percentage yield percentage rates for 
routine bronchoscopic specimens range from the mid-teens to mid 80’s depending on the lesion 
size (<20mm or >20mm), location, the presence of an airway leading into the lesion and means 
of biopsy or combination of biopsy methods.  The vast majority of the studies reviewed have 
focused on suspected lung cancer with the diagnostic yield in other malignancies or metastatic 




i. Sampling of Parenchymal lesions by Endobronchial Brushings 
A variety of commercially available cytology brushes sharing similar characteristics of 
flexible bristles encased within a sterile single use sheath are available.  Bristle diameters range 
from 1.2-3 mm with the length of the brush typically measuring 10 mm.  The tip is usually 
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rounded and metallic for improved visualization while utilizing fluoroscopy.  The procedure may 
be performed using moderate sedation or general anesthesia.  After adequate sedation, the 
bronchoscope is advanced into the broncho-pulmonary segment of interest and then using either 
fluoroscopy or navigational guidance, the brush sheath is advanced to the leading edge of the 
lesion. The brush is then extruded from its sheath through the bronchoscope and advanced 1-3 
cm into the area of interest followed by a back and forth motion for several seconds while 
visualized by fluoroscopy.  The brush is then retracted into the sheath and removed from the 
bronchoscope, after which the tip can be immediately extruded and brushed onto a slide, which 
is then placed into fixative solution, or clipped into a sterile specimen cup with normal saline for 
processing at a later time. This process is then repeated between 2 and 6 times.  Several 
techniques such as brush rotation and repeated brushing have been described, however, no 
specific technique has been shown to definitively increase yield or diagnostic accuracy.  There is 
also no consensus on number of brushings that should be performed.  One older study has shown 
that brushes with longer, wider bristles provided a greater yield in the number of cells per 
brush.
59
 It is generally accepted that performing brushings prior to biopsies is preferable due to 
decreased peripheral blood contamination.  
ii. Radial EBUS (R-EBUS) and Transbronchial Needle Aspiration (TBNA) 
 Radial EBUS and navigational bronchoscopy are adjunctive technologies which provide 
the clinician additional directional and spatial information as to where to direct brushes and/or 
forceps to improve diagnostic accuracy.  R-EBUS guidance is utilized to confirm accurate 
localization of a PPL prior to biopsying it.  This is particularly useful when the PPL is in a 
peripheral location and requires navigation through multiple branching airway segments to reach 
it.  When multiple branches need to be traversed, navigation bronchoscopy can be utilized to 
efficiently and accurately guide the bronchoscopist to the correct subsegmental airway at which 
point R-EBUS can be used to confirm arrival at the target PPL. 
R-EBUS biopsies are performed during bronchoscopy either using moderate sedation or 
general anesthesia.  The use of fluoroscopy during the procedure is operator dependent. Using a 
reference CT scan the bronchoscope is directed into the appropriate bronchopulmonary segment 
after which a guide sheath containing a 20mHz probe is then slowly advanced until visualization 
of the intended lesion is obtained.  The probe is then withdrawn from the sheath, the biopsy 
instrument is advanced through the sheath, and biopsies are obtained.  Published literature results 
show a range of findings. In one study, histologic diagnosis was confirmed in 69% of patients 
using R-EBUS alone, and in 88% of patients using a combination of R-EBUS and 
Electromagnetic Navigational bronchoscopy (EMN)
60
.  Results from the AQuIRE Registry failed 
to show significant contributions with the addition of either R-EBUS or EMN;
61
 while they did 
show increased diagnostic yield with peripheral TBNA (47.4%), it was noted that this particular 
device was underutilized.  The most common cytology needles used for the procedure are either 
22 or 21 G, but ranging from 19-21 G.  As with transthoracic needle aspiration, there are no large 
studies demonstrating differences in yield rates for different needle gauges.   
iii. CT-Guided Transthoracic Needle Aspiration: 
CT-FNA is a minimally invasive procedure that is used to evaluate various lung lesions, 
particularly peripheral ones.
3
 Transthoracic needle aspiration is able to provide diagnosis of 
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peripheral lung lesions with a diagnostic accuracy in the range of 85-95% in many studies.  Its 
two primary complications are pneumothorax and intraparenchymal bleeding.  The procedure 
involves injecting a local anesthetic from the skin to the pleural surface followed by smooth 
advancement of the respective needle briskly through the pleural surface into the lung 
parenchyma and ultimately into the lesion as directed by CT visualization.  The procedure may 
be performed using either intravenous moderate sedation or general anesthesia.  Diagnostic rates 
vary depending upon lesion size and location.  Pneumothorax rates are approximately 10-25% 
with only a small percentage of patients requiring closed tube thoracostomy.  There remains no 
consensus as to the needle gauge recommended for the procedure.  Nearly all comparisons of 
fine needle aspiration biopsy (FNAB) and cutting needle biopsy have been based only on the 
capacity to differentiate between benign and malignant lesions.
62
 That same single center 
retrospective study with a total of 434 consecutive outpatients demonstrated sensitivity, 
specificity, and accuracy rates for a 22 G Chiba type needle (cytology) of  82.6%, 81.3% and 
81.8% with the respective values for an automated 20 gauge coaxial system (histology) of 
93.8%, 97.3% and 95.2%.  A variety of cytology needles with gauges ranging from 20-25 G and 
core biopsy or histological needle gauges ranging from 22-18 G are currently available.  With the 
increasing availability of ROSE; once diagnosis is confirmed by a minimal number of passes, 
additional passes may be collected for cell block and immunohistochemical stains or mutational 
analysis.  The number of passes needed per procedure has not been defined and may vary based 
on the availability of ROSE.
63
 Generally at least two passes are recommended. 
 
II. Guidelines for Use of Rapid On Site Assessment (ROSE) 
A. Overview 
ROSE is an interactive process involving the cytopathology team and the clinical team that 
performs the FNA. ROSE can influence the effectiveness of FNA in terms of acquiring sufficient 
tissue for diagnosis and appropriately triaging samples for ancillary tests, as well as by providing 
immediate direct feedback to the clinical team that performs the image-guided FNA.  Collins et 
al. demonstrated greater efficiency of EBUS-guided FNA procedure along with substantial 
improvement in health care resource utilization upon the implementation of ROSE.
64
  Ideally, 
both on-site adequacy and preliminary diagnosis should be included when reporting ROSE. 
There is limited literature focusing on a detailed protocol for performing ROSE. 
While slide preparation may vary slightly among institutions, the most commonly 
followed procedure is that for each pass, a small portion of the sample is used to produce 2 
smeared slides.   Positively charged slides are recommended to enhance cellular retention during 
processing.   One smear is used for the ROSE and stained with one of the commercially available 
fast staining methods.  The most commonly used method is The Diff-Quik method on an air 
dried slide which takes approximately 30 seconds to perform and does not require mounting 
media and cover slipping for the initial review.  The second slide is traditionally fixed with 
alcohol and stained with the Papanicolaou stain.  The needle is then rinsed into a cell collection 
medium (such as saline, RPMI or CytoLyt) for cell block preparation.  Depending on the 
preliminary diagnostic differential generated from ROSE, other appropriate collecting media 
may be used for additional samples e.g. culture tubes for microbiology, RPMI for flow 
cytometry, etc.  In the event of a carcinoma diagnosis, additional passes are collected for 
ancillary testing which include immunohistochemistry to further classify the carcinoma and 
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molecular testing.  While a cell block is generally favored, smears can also be utilized for these 
tests if properly validated.   
There is no fixed number of needle passes. Instead, the number of passes is determined 
by the preliminary adequacy, diagnosis, and the need for additional material for potential testing, 
provided that the patient can tolerate the additional passes.  Although ROSE has been shown to 
reduce the number of recall procedures due to inadequate tissue procurement, ROSE is not a 
good predictor of an adequate cell block for biomarker and molecular studies. 
Documentation of ROSE should include the following information: patient name with 
two identifiers (e.g. date of birth and medical record number), site of aspiration, size of lesion, 
total number of needle passes, number of Diff Quik- and Pap-stained slides, choice of cell 
block/ThinPrep or other concentration technique, any additional material obtained for ancillary 
studies (i.e. flow cytometry, microbiology), preliminary diagnosis, the clinician who is notified 
of the preliminary result, names of cytology personnel, and date of the procedure.  The ROSE 
documentation should be incorporated into the final cytology report.  
 
B. ROSE for Sampling Mediastinal Lymph Nodes   
Despite the lack of uniform criteria for adequacy assessment and standardized reporting, 
there are a few published studies that explored this topic.  The University of Minnesota 
semiquantitatively assessed the number of lymphocytes under x40 magnification with a score of 
0-3. A score of 0 (<40 lymphocytes) was considered inadequate versus a score of 1 (>40 
lymphocytes) or more, alternatively, the presence of clusters of anthracotic pigment-laden 
macrophages which was considered representative of lymph node sampling and therefore 
diagnostic.  Contamination with bronchial epithelial cells has no influence on adequacy 
assessment.  Samples with malignant cells or granulomas are considered diagnostic regardless of 
the number of lymphocytes present.  Five diagnostic categories were reported, including non-
diagnostic, benign, atypical cells, suspicious for carcinoma, and malignant.  The data 
demonstrated that immediate on-site interpretation correlated well with final cytological 
diagnosis.
65
   
 
However, some found that it is difficult to apply the above scoring criteria to all cases 
while performing adequacy assessment.  Instead, a retrospective study using the same reporting 
categories and comprising 131 cases of mediastinal lymph node specimens defined samples as 
non-diagnostic or benign according to the following criteria: 1) Non-diagnostic - no lymphocytes 
were found in lymph node sampling; 2) Benign - without evidence of tumor, moderate to 
abundant number of  lymphocytes were found in lymph node sampling.
66
  With the aim of 
defining practical and useful on-site adequacy criteria, another retrospective study established the 
requirement for adequacy as follows: 1) any smear with > 5 low power fields (x100 
magnification) each containing at least 100 lymphocytes and < 2 groups of bronchial cells; 2) 
any smear with germinal center fragments; 3) any smear with abnormal results such as 
malignancy or granuloma.  Using this approach, adequacy assessment correlated well with both 
the final cytological diagnosis and the surgical follow-up.  Together with effective cytologist-
clinician communication, an algorithmic approach to diagnosis and the proposed adequacy 
criteria can markedly improve the diagnostic yield.
67
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To minimize intra- and inter-institutional reporting variability and to establish a 
standardized ROSE reporting system, Jeffus, et al retrospectively applied the two 
aforementioned institutional reporting systems to their own study cohort. Their on-site adequacy 
rates determined by using the two separate systems were almost identical (85% vs. 86%).  The 
authors recommended a combined modified system, consisting of the adequacy assessment 
criteria and the tiered diagnostic system.
68
   
 
C. ROSE for Sampling Lung Masses   
Although the advantages and disadvantages of ROSE for sampling lung lesions have been 
discussed, few studies describe the adequacy criteria and reporting categories. In practical terms, 
adequacy criteria for lung mass FNA are self-evident.  One study of the role of ROSE for CT-
guided FNAs of lung nodules mentioned that a smear was considered inadequate if it contained 
poorly preserved cells or the cellularity was scanty and not compatible with the clinical and/or 
radiologic impressions.
67
 Similarly, another study  defined a specimen as inadequate when no 
malignant cells or sufficient site-specific tissue is present.
69
  A retrospective study including 64 
FNA specimens of lung lesions defined samples as non-diagnostic and benign depending on the 
absence and presence of bronchial epithelial cells or pigmented macrophages, respectively.  A 
recently published prospective study defined an adequate specimen as one that consisted of 






III. Guidelines For Obtaining, Transporting, and Processing Specimens for 
Immunochemistry, Flow Cytometry, and Molecular Testing 
Established protocols for handling cytology samples of solid tumors are limited, and the 
best example is evaluation of HER2 expression in breast cancer.
71
 There is great variation among 
laboratories for processing non-gynecological cytology.
72-74
 Small biopsies and cytology 
specimens from patients with lung cancer are often the first, and in some cases, the only 
available material for diagnostic work-up.
75
  These samples are often used for molecular 
characterization for predictive markers, which are essential for the selection of appropriate 
patient therapies
76
   In addition, sub-classification of non-small cell carcinoma into 
adenocarcinoma versus squamous cell carcinoma has become a necessity for guiding patient 
management.  Therefore, the use of immunocytochemical panels that can aid in the 
subclassification of NSCLC are an essential tool.
77,78
 When lung cancer is in the differential 
diagnosis, tissue triage that allows for potential future molecular testing of the diagnostic 
material should be implemented by each laboratory following multidisciplinary discussions 
involving pathologists, interventionist, and other clinicians. 
Rapid onsite evaluation (ROSE) is encouraged, as it has been demonstrated to reduce the 
need for subsequent procedures, and it allows for efficient triage of sampled tissues.
79
 During 
tissue procurement, it is recommended that an effort be made to reduce the number of direct 
smears produced, thereby preserving more material for subsequent studies.  Although many 
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laboratories have effectively validated protocols for the use of smears for immunocytochemistry 
and molecular analysis, this practice is not recommended by the College of American 
Pathologists (CAP) as the most reliable source of material for molecular testing.
80
  If direct 
smears are to be used as a source of DNA for molecular studies, additional measures such as 
digital scanning of original slides to generate a virtual copy are recommended by many legal 
experts since smears may be the only documentation of disease in some cases of advanced lung 
carcinoma.  When possible, one air dried, modified Diff Quik stained smear or one alcohol fixed, 
Papanicolaou stained smear should be examined at the time of the procedure to determine 
adequacy, and the reminder of the aspirate should be placed into a suitable transport liquid for 
further triage and processing.   In addition, core biopsies are sometimes obtained at the time of 
the FNA to supplement the cytological material.  Core biopsies should be placed into fixative 
(buffered formalin) and transported to the laboratory for histologic processing.   
When the diagnosis of lung cancer is suspected or confirmed during ROSE, the aspirates 
should ideally be fixed in alcohol or buffered formalin until further processing. The use of 
alcohol is generally preferred for material that is going to be used for molecular testing since the 
yield of nucleic acid is greater with less degradation artifacts. However, alcohol fixation can 
present problems for immunocytochemical analysis. The immunohistochemical protocols 
developed for formalin-fixed tissue may not apply completely to alcohol fixed material.  Thus, 
requiring validation of each antibody for alcohol-fixed tissue.  In addition, there are some 
antibodies that are less effective when applied to alcohol fixed-tissue even after rigorous 
validation attempts.
81
 More importantly, improvements in the ability to extract DNA from 
formalin-fixed paraffin-embedded (FFPE) tissue have been made. 
When a lymphoproliferative lesion is suspected during triage of the specimen, unfixed 
material for flow cytometry should be obtained.  In these cases, the unfixed sample can be 
collected and transported in an isotonic fluid such as cell culture medium (RPMI for example) or 
enriched saline (Hank’s solution).  If needed for diagnostic purposes, an aliquot of the material 
can be used to produce a liquid-based preparation, but adequate material should be reserved for 
flow cytometric analysis.  An alternative protocol is to split the obtained material for flow 
cytometry and an FFPE cell block that can be used for further classification of the lymphoid cells 
typically by immunohistochemical evaluation.   
When additional dedicated aspirates are deemed necessary for ancillary studies, this 
should be communicated to the interventionist.   If further passes are obtained, it is important to 
check each pass for adequacy. 
Cell block preparations are an important tool for tumor analysis, and they provide a 
means of preserving tissue for long-term storage and for future discoveries.  In addition, cell 
block preparations are the recommended method by CAP for molecular studies
80
.   Cell blocks 
allow for quality assurance and control, since the number and quality of the neoplastic cells can 
be estimated as well as the presence of other cell types that may influence subsequent analysis. 
For molecular studies, the number of tumor cells and the amount of tumor nuclei in the 
preparation are essential components for an adequate performance. The presence of necrotic 
debris and number of contaminating lymphocytes can influence results. Most molecular 
techniques can now detect allelic alteration in less than 5% of tumor nuclei, but if the majority of 
DNA comes from benign lymphocytes and the molecular alteration is present at a low rate in 
tumor cells, a false negative result could result. Several studies have assessed the minimum 
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number of tumor cells required for evaluation.  Although the number depends upon the 
molecular test preformed, a general estimate is a minimum number of 2000 tumor cells, and the 




 The use of cytology in the diagnosis of pulmonary disease and in particular pulmonary 
cancer has increased tremendously especially in the era of personalized therapy.  In that respect, 
diagnosis of lung cancer by cytology especially TBNA has been the prototype for many future 
applications to other cancers.  This series of publications are focused on establishing an in depth 
understanding of the different cytology sampling techniques, their indications, methodology and 
handling the collected specimens. The additional application of ancillary techniques such as 
immunocytotochemistry and molecular testing mandates that the limited cytology samples be 
efficiently utilized to maximize the results and avoid additional more invasive sampling 
methods.  It is logical to anticipate that future publications will focus on standardizing the 
processing methodology for DNA and RNA retrieval and for building proper biorepositories.  
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Figure 1. The mediastinal and hilar lymph nodes generally accessible via EBUS bronchoscopy. A) AP 
coronal view and B) right-sided sagittal view of the mediastinum and hila.   
Figure 2. A) Enlarged subcarinal (7) lymph node seen on cross-sectional CT image. B) Level 7 lymph node 
undergoing real-time EBUS TBNA.   
Figure 3. Anatomy of the EBUS bronchoscope tip with viewing angles.   
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